KR102744830B1 - 발달 장애 치료에 있어서, (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산 및 관련된 화합물들, (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 사이클로펜탄 -1-카르복실산 및 비가바트린의 사용 - Google Patents

발달 장애 치료에 있어서, (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산 및 관련된 화합물들, (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 사이클로펜탄 -1-카르복실산 및 비가바트린의 사용 Download PDF

Info

Publication number
KR102744830B1
KR102744830B1 KR1020217000541A KR20217000541A KR102744830B1 KR 102744830 B1 KR102744830 B1 KR 102744830B1 KR 1020217000541 A KR1020217000541 A KR 1020217000541A KR 20217000541 A KR20217000541 A KR 20217000541A KR 102744830 B1 KR102744830 B1 KR 102744830B1
Authority
KR
South Korea
Prior art keywords
per day
delete delete
amino
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217000541A
Other languages
English (en)
Korean (ko)
Other versions
KR20210035802A (ko
Inventor
매튜 듀링
브렛 아브라함스
Original Assignee
오비드 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오비드 테라퓨틱스 인크. filed Critical 오비드 테라퓨틱스 인크.
Publication of KR20210035802A publication Critical patent/KR20210035802A/ko
Application granted granted Critical
Publication of KR102744830B1 publication Critical patent/KR102744830B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020217000541A 2018-06-07 2019-06-07 발달 장애 치료에 있어서, (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산 및 관련된 화합물들, (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 사이클로펜탄 -1-카르복실산 및 비가바트린의 사용 Active KR102744830B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862681913P 2018-06-07 2018-06-07
US62/681,913 2018-06-07
PCT/US2019/035934 WO2019236938A1 (en) 2018-06-07 2019-06-07 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Publications (2)

Publication Number Publication Date
KR20210035802A KR20210035802A (ko) 2021-04-01
KR102744830B1 true KR102744830B1 (ko) 2024-12-19

Family

ID=68765508

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217000541A Active KR102744830B1 (ko) 2018-06-07 2019-06-07 발달 장애 치료에 있어서, (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산 및 관련된 화합물들, (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 사이클로펜탄 -1-카르복실산 및 비가바트린의 사용

Country Status (12)

Country Link
US (3) US10813899B2 (https=)
EP (1) EP3813816B1 (https=)
JP (1) JP7387179B2 (https=)
KR (1) KR102744830B1 (https=)
CN (1) CN112770739B (https=)
AU (1) AU2019280980B2 (https=)
CA (1) CA3102786A1 (https=)
ES (1) ES2948263T3 (https=)
IL (2) IL279220B2 (https=)
MX (2) MX2020013290A (https=)
PL (1) PL3813816T3 (https=)
WO (1) WO2019236938A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279220B2 (en) 2018-06-07 2023-12-01 Ovid Therapeutics Inc Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders
GB2591389A (en) 2018-08-18 2021-07-28 Ftf Pharma Private Ltd Pharmaceuticals solution for oral dosage
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition
AU2024220546A1 (en) * 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid for gastrointestinal tract disorders and as an immunomodulatory agent
CN120641091A (zh) * 2023-02-17 2025-09-12 奥维德医疗公司 (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗糖尿病和前驱糖尿病中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
WO2005120496A2 (en) 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
WO2009033818A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
WO2012042314A1 (en) 2010-10-02 2012-04-05 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US20140315992A1 (en) 2011-07-07 2014-10-23 The Children's Hospital Of Philadelphia Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism
EP2806867A4 (en) 2012-01-27 2015-09-02 Catalyst Pharmaceutical Partners Inc METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS
TW201606304A (zh) * 2013-09-09 2016-02-16 亞克柏拉有限公司 測定治療反應之方法
US20150224164A1 (en) 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
CA2966642C (en) 2014-11-07 2023-03-28 Northwestern University Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
EP3341355B1 (en) 2015-10-09 2020-09-30 Northwestern University (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma
US10632088B2 (en) 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
EP4692048A3 (en) * 2017-02-08 2026-04-01 Ovid Therapeutics Inc. Methods of treating cdkl5 disorders with the compound ov329
AU2018370164B2 (en) * 2017-11-14 2024-08-15 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome
KR20250051780A (ko) 2018-05-25 2025-04-17 노오쓰웨스턴 유니버시티 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의합성을 위한 공정
IL279220B2 (en) 2018-06-07 2023-12-01 Ovid Therapeutics Inc Use of (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid and related compounds, (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and vigabatrin In the treatment of developmental disorders

Also Published As

Publication number Publication date
CN112770739B (zh) 2023-12-12
IL304270A (en) 2023-09-01
CA3102786A1 (en) 2019-12-12
IL304270B1 (en) 2024-06-01
MX2020013290A (es) 2021-04-29
AU2019280980A1 (en) 2021-01-07
EP3813816B1 (en) 2023-06-07
US11660277B2 (en) 2023-05-30
KR20210035802A (ko) 2021-04-01
AU2019280980B2 (en) 2025-02-27
IL279220B2 (en) 2023-12-01
IL279220A (en) 2021-01-31
PL3813816T3 (pl) 2023-07-31
ES2948263T3 (es) 2023-09-07
US12285397B2 (en) 2025-04-29
IL279220B1 (en) 2023-08-01
WO2019236938A1 (en) 2019-12-12
US20230255914A1 (en) 2023-08-17
EP3813816C0 (en) 2023-06-07
US20210100763A1 (en) 2021-04-08
US10813899B2 (en) 2020-10-27
JP7387179B2 (ja) 2023-11-28
CN112770739A (zh) 2021-05-07
MX2023006497A (es) 2023-06-21
US20190374492A1 (en) 2019-12-12
EP3813816A4 (en) 2021-06-23
JP2021527053A (ja) 2021-10-11
IL304270B2 (en) 2024-10-01
EP3813816A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
KR102744830B1 (ko) 발달 장애 치료에 있어서, (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산 및 관련된 화합물들, (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 사이클로펜탄 -1-카르복실산 및 비가바트린의 사용
TWI819995B (zh) 以加波沙朵（ｇａｂｏｘａｄｏｌ）治療發育障礙的方法
US11590107B2 (en) Methods for treating neurological disorders with α1A-AR partial agonists
US20100063116A1 (en) Use of pramipexole or a salt thereof for the treatment of parkinson's disease
US10653652B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
US20190328719A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
HK40050398B (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
HK40050398A (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
WO2020018779A1 (en) Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction
US11771671B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
JP6738797B2 (ja) レット症候群治療薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220603

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240122

Patent event code: PE09021S01D

PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240921

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241216

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241216

End annual number: 3

Start annual number: 1

PG1601 Publication of registration